Johan Bylund

Johan Bylund is an accomplished professional in the fields of pharmacokinetics and clinical pharmacology, currently serving as Director of DMPK and Clinical Pharmacology at CTC Clinical Trial Consultants AB since March 2019, alongside roles as Scientific Advisor and Board Member at MetaSafe since September 2022. With a robust background, Bylund has held significant positions such as Principal Scientist in DMPK at Medivir AB and DMPK Project Leader at Roche, contributing to the advancement of multiple drug candidates, including the DMPK-optimized Risdiplam. Bylund’s academic credentials include a PhD in Biochemical Pharmacology from Uppsala University and postdoctoral research at the Medical College of Wisconsin, in addition to multiple educational pursuits in pharmacy. Overall, Bylund's extensive experience in both preclinical and clinical settings underscores a strong commitment to advancing pharmacological science.